India is rapidly cementing its position as a global powerhouse in the medical devices industry, driven by robust policy support, rising manufacturing capabilities, and increasing global demand for high quality, affordable medtech solutions. With a combination of strong domestic reforms and strategic international partnerships, the
Event organized by Informa Markets in India to bring over 2,000 exhibitors & 50,000 industry participants from more than 120 countries under one roof.Organized by Informa Markets in India, the 18th edition of CPHI & PMEC India 2025, South Asia's largest and most influential pharmaceutical industry event, is scheduled
Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre- Approval Inspection (PAI) conducted between
Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda Eli Lilly and Company today announced plans to invest more than $1 Billion over the next several years into new contract manufacturing in India, expanding patients’ access to innovative
Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26. Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins) Q2 FY25Q2 FY26YoY Change (%)Revenue from Operations8919112%Reported Revenue9089262%Reported EBITDA261215-18%Reported EBITDA margin (%)28.8%23.2% Reported PAT (before exceptional items)10667-37%Reported PAT Margin (%)11.7%7.3% H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins) H1 FY25H1 FY26YoY Change (%)Revenue from Operations1,6811,7856%Reported Revenue1,7151,8186%Reported EBITDA449439-2%Reported EBITDA margin (%)26.2%24.1% Reported PAT (before exceptional items)161*154-4%Reported PAT Margin (%)9.4%8.5% Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim. Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Our Q2 performance was driven by underlying revenue growth from research
India’s leading vaccine innovator Bharat Biotech has announced the establishment of a Contract Research, Development, and Manufacturing Organization (CRDMO) division dedicated to cell and gene therapy, marking a strategic expansion into one of the most advanced frontiers in biomedical science. The new CRDMO arm will focus
The Yamuna Expressway Industrial Development Authority (YEIDA) is all set to sign a Memorandum of Understanding (MoU) with a leading Japanese government agency — the Japan External Trade Organization (JETRO) — to collaborate on the development of a state-of-the-art Medical Device Park along the Yamuna
In a move to strengthen drug regulation and ensure the availability of safe, high-quality medicines, Uttar Pradesh Chief Minister Yogi Adityanath announced that the state government will double the number of drug inspectors across the state. The decision is aimed at improving the monitoring of
Built on the values of Confidence, Care and Science, KeyCi is rooted in dermatological research and sustainabilityIberia Pharmaceuticals, a leading name in skincare, has launched KeyCi, a science-backed skincare brand designed for modern consumers aged 18–45. KeyCi offers high-performance, dermatologically tested products that are vegan,
Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies servicesSyngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully
